Business Context and Reporting Period
Company: Conduit Pharmaceuticals Inc. (CDT)
Filing Type: Form 8-K (Current Report)
Date of Report: December 12, 2024
Event: Entry into a Material Definitive Agreement with SARBORG Limited ("Sarborg").
Key Financial Metrics and Transaction Details
This filing reports a specific contractual agreement rather than periodic financial performance. Key financial terms of the agreement include:
- Initial Cash Payment: $200,000.
- Initial Equity Payment: $200,000 payable via issuance of 2,272,727 shares of common stock (valued at the closing price the day preceding execution).
- Milestone Payments: Up to $1,800,000 payable in cash or shares at Conduit's discretion upon achieving specific milestones.
- Expenses: Reimbursement of pre-approved, necessary, and reasonable out-of-pocket expenses.
- Term: Initial term of 12 months, renewable by mutual written agreement.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the company.
Material Changes and Agreement Structure
The agreement establishes a three-phase service delivery model for algorithmic and cybernetic technology services:
- Initial Phase (0-24 weeks): Foundation establishment and strategic alignment.
- Development Phase (24-36 weeks): Infrastructure building, including dashboards and predictive models.
- Ongoing Services Phase (36-52 weeks): Sustained functionality, iterative improvements, and updates.
Intellectual Property: Sarborg retains ownership of pre-existing IP; Conduit owns all deliverables created under the agreement.
Registration Rights: Sarborg receives registration rights for the common stock issued as consideration, requiring Conduit to register shares within 60 days of issuance and make the statement effective within 90 days of filing.
Management Commentary, Risks, and Related Parties
Related Party Transaction: Dr. Andrew Regan, a member of Conduit's Board of Directors, also serves on the Board of Directors of Sarborg.
Termination: Either party may terminate for any reason with 90 days' written notice, or immediately for material breach (uncured within 30 days) or insolvency.
Outlook: The agreement aims to enhance decision-making processes and maximize the value of Conduit's pharmaceutical asset portfolio through advanced cybernetic systems.
Investor Verification Checklist
- Verify the closing price of CDT stock on December 11, 2024, to confirm the valuation of the 2,272,727 shares issued.
- Review the specific milestones defined in the full Services Agreement (Exhibit 10.1) to assess the likelihood of the $1.8 million in potential future payments.
- Confirm the dilution impact of the 2,272,727 shares on existing shareholders.
- Assess the related party nature of the transaction given Dr. Regan's dual board membership.
- Monitor the timeline for the registration statement filing and effectiveness as required by the agreement.